SynergyMed

SynergyMed has developed a cure for cancer that takes just ten minutes to administer.

This non-surgical solution has destroyed cancerous tumors in mice and dogs, and did so without damaging surrounding healthy tissue, causing cosmetic deformities, or affecting the subject’s quality of life. Now the company has its sights set on destroying similar tumors in humans.

Sixty percent of those diagnosed with cancer undergo surgery. But surgery is expensive, risky, and invasive. It also offers no guarantee of long-term success.

These problems are what makes SynergyMed’s solution so extraordinary. Here’s how it works:

The company has developed a non-surgical, non-invasive solution to destroy cancer tumors. In other words, it’s created a non-invasive ablation device. Ablation is a medical procedure that involves destroying or removing abnormal tissue or cells.

This solution combines electromagnetic energy in the form of microwaves and radio frequency with special nanoparticles, a form of nanotechnology that is designed to make a beeline for a tumor and release drugs at a controlled rate. The idea is to kill off cancerous cells while sparing healthy ones.

First, tumors are injected with these nanoparticles, which act like sponges for the electromagnetic energy that’s then applied non-invasively. When combined, the energy and nanoparticles heat the tumor. Eventually, the heat reaches a level that the tumorous cells can’t withstand — and thus, they’re destroyed. Notably, healthy tissue isn’t affected because it doesn’t contain the nanoparticles.

SynergyMed uses proprietary computer algorithms to control temperature and dosing, ensuring it can effectively destroy the cancerous cells. This synergistic effect leads to maximum destruction of tumors — with minimal energies and with no damage to healthy tissue.

SynergyMed’s technology is presented in two systems, one designed for animals and one for humans. These systems can treat multiple tumors simultaneously and require little image guidance, which is the use of imaging technology to assist with surgery (very expensive).

SynergyMed plans to sell its systems to veterinary and human clinics. It will also sell consumables used to treat each patient — single-use items like syringes, bandages, and masks that are essential for patient care and safety.

Its veterinary device will sell for $100,000 and the human device will sell for $200,000.

According to Grand View Research, the veterinary oncology market is projected to surpass one billion dollars by 2030. And the market of breast-cancer surgery treatment alone is close to nine billion dollars globally. All told, the global market for cancer surgery is valued at fifty billion dollars.

SynergyMed has signed Letters of Intent (LOIs) from Boston Scientific and Medtronic and projects to generate $500 million in revenue within the next five years.

It will continue to run clinical studies treating tumors in dogs, and aims to start generating sales of its veterinary device later this year.

Team Background

Anan Copty - Chief Executive Officer

Anan has more than twenty-five years of technical and leadership experience.

Prior to starting SynergyMed, he founded NIMD, a medical-device company aiming to treat cancer by combining microwave and metal-based nanoparticles — similar to SynergyMed’s mission. He started NIMD after spending a decade with Intel as a senior R&D physicist.

Earlier in his career, he was a staff scientist with Radiation Monitoring Devices, a company focused on radiation detection and imaging. Before that, he was an R&D physicist at Harvard Medical School, where he built and tested radio-frequency technology for Magnetic Resonance Imaging (MRI) applications. He began his career as a research assistant at Harvard’s Physics Department.

Anan earned a Bachelor’s degree in Physics from Gordon College, a Master’s degree in Physics from Boston College, and a Ph.D. in Physics from the Hebrew University of Jerusalem.

Daniel Kacher - Director of Clinical Studies

In addition to his role with SynergyMed, Dan has spent the past twenty-eight years at Brigham and Women’s Hospital in Boston.

He spent the first fourteen years as a senior project manager in the hospital’s radiology department, and has served as a senior-clinical engineer since 2011. His main task in this role is to support clinical efforts for an advanced multi-modality image guided operating suite (AMIGO), which involves an MRI scanner that travels to the patient.

Prior to starting at this hospital, Dan was a fellow at Harvard Medical School. He earned a Bachelor’s degree in Biomedical Engineering from Rensselaer Polytechnic Institute, a Master’s in Biomedical Engineering from Boston University, and a Ph.D. in Electrical Engineering from Northeastern University.

Yahya Dajani - VP of Business Development

Yahya began his career at ADNOC Group, one of the world’s leading energy producers based in Abu Dhabi. He worked as a performance and contracts analyst and a corporate planning advisor.

From there, he was a managing director for a consulting business, then became Vice President of Sales with NCA Scientific Monitoring, part of National Compliance Australia, a company dedicated to bringing scientific education to hospitals around the world.

He earned a Bachelor’s degree in Entrepreneurship from the University of Oregon.

Co-Investors